Bausch Health Companies Inc (BHC.TO) has seen a steady rise in its stock performance recently, driven by a mix of company announcements and market activity.
This week, Bausch Health Companies Inc experienced positive price action, closing at C$9.11, marking a 2.15% increase for the day and a 3.68% rise over the week. Investors have reacted to several recent announcements from the company, contributing to this upward momentum.
Investor takeaway: While Bausch Health's stock has shown a notable increase in the short term, investors should remain cautious given the bearish outlook from analysts and the company's current financial metrics.
Advertisement
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$3.09B
52W high
$11.08
52W low
$6.10
1W change
-11.06%
Beta
0.37
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to fall 11.1% over the next 12 months.
Consensus
Moderately BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
-11.1% Upside
Current Price
C$7.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
54.0%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$9.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.36 | C$6.94 – C$10.08 |
| 60 trading days | C$8.88 | C$6.82 – C$11.55 |
| 90 trading days | C$9.42 | C$6.82 – C$13.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bausch Health's stock has surged 31.68% over the past month. Despite recent gains, its year-to-date performance is still down by 9.07%, highlighting ongoing challenges.
Bull case
Recent announcements, including the winners of the Gastrointestinal Health Scholars Program and updates from Bausch + Lomb's board, indicate a commitment to innovation and leadership in the health care sector. This focus could boost investor confidence.
Bear case
Despite the recent gains, analysts maintain a bearish outlook, with an average target price significantly lower than the current stock price. This suggests potential challenges ahead for the company.
Recent Company News
Bausch Health has made headlines with several announcements this month. Notably, the company announced the winners of its 2026 Gastrointestinal Health Scholars Program, showing its commitment to supporting education in the health sector. Additionally, CEO Thomas J. Appio has joined the board of Bausch + Lomb, signaling a strategic alignment within the company's leadership. These updates reflect the company's ongoing commitment to innovation and improvement in its service offerings.
Technical Picture
Bausch Health's stock is currently trading at C$9.11, well above its 50-day moving average of C$7.24, representing a 25.9% increase. Its 200-day moving average stands at C$8.10, indicating a 12.5% rise from the current price. The stock has a 52-week range of C$6.10 – C$11.64, suggesting that it is currently trading at 54% of its range. The beta of 0.38 indicates lower volatility compared to the broader market, while the current trading volume of 581,296 shares is below the 20-day average volume of 819,105 shares.
Advertisement
Insider Activity
There has been no significant insider activity reported this week for Bausch Health Companies Inc. This could suggest a period of stability among the company's executives, though investors may want to keep an eye on any future insider transactions for potential insights into management's confidence in the company's direction.
Analyst Outlook
Analysts have set an average target price of C$7.01 for Bausch Health, implying a potential downside of 23.1% from the current trading price. The outlook remains bearish, reflecting concerns over the company's financial performance, including a profit margin of -10.1% and a negative EPS of -4.09. Investors should consider these factors when evaluating the stock's potential for future growth.
Price Action Summary
Bausch Health Companies Inc closed at C$9.11, marking a 2.15% increase for the day and a 3.68% rise for the week. Despite the recent positive momentum, the stock's year-to-date performance remains down by 9.07%, indicating ongoing challenges that investors should be aware of.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
